Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew T Drake

Showing results (21-30 of 120) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|November 26, 2008
Effects of bortezomib on bone disease in multiple myelomaMatthew T Drake, S Vincent Rajkumar
Mayo Clinic Proceedings|May 6, 2018
Failing Kidneys and Thyroid Dysfunction-An Undesirable SynergyMarius N Stan, Matthew T Drake
Bonekey Reports|March 1, 2014
Clinical utility of serum sclerostin measurementsBart L Clarke, Matthew T Drake
Current Opinion in Supportive and Palliative Care|August 6, 2013
Vitamin D in the cancer patientKurt A Kennel, Matthew T Drake
Mayo Clinic Proceedings|July 2, 2009
Adverse effects of bisphosphonates: implications for osteoporosis managementKurt A Kennel, Matthew T Drake
Mayo Clinic Proceedings|July 3, 2024
The Long and Winding Road to Improving Bone Mineral Density Testing and ReportingKurt A Kennel, Matthew T Drake
Current Opinion in Rheumatology|May 9, 2014
Inhibitors of sclerostin: emerging conceptsMatthew T Drake, Joshua N Farr
Metabolism: Clinical and Experimental|April 7, 2023
Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults"Ghada El-Hajj Fuleihan, Matthew T Drake
Mayo Clinic Proceedings|September 9, 2008
Bisphosphonates: mechanism of action and role in clinical practiceMatthew T Drake, Bart L Clarke, Suneep Khosla
Molecular Interventions|June 12, 2010
Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibitionMatthew T Drake, Serge C L M Cremers
Pageof 12

Showing results (21-30 of 120) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|November 26, 2008
Effects of bortezomib on bone disease in multiple myelomaMatthew T Drake, S Vincent Rajkumar
Mayo Clinic Proceedings|May 6, 2018
Failing Kidneys and Thyroid Dysfunction-An Undesirable SynergyMarius N Stan, Matthew T Drake
Bonekey Reports|March 1, 2014
Clinical utility of serum sclerostin measurementsBart L Clarke, Matthew T Drake
Current Opinion in Supportive and Palliative Care|August 6, 2013
Vitamin D in the cancer patientKurt A Kennel, Matthew T Drake
Mayo Clinic Proceedings|July 2, 2009
Adverse effects of bisphosphonates: implications for osteoporosis managementKurt A Kennel, Matthew T Drake
Mayo Clinic Proceedings|July 3, 2024
The Long and Winding Road to Improving Bone Mineral Density Testing and ReportingKurt A Kennel, Matthew T Drake
Current Opinion in Rheumatology|May 9, 2014
Inhibitors of sclerostin: emerging conceptsMatthew T Drake, Joshua N Farr
Metabolism: Clinical and Experimental|April 7, 2023
Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults"Ghada El-Hajj Fuleihan, Matthew T Drake
Mayo Clinic Proceedings|September 9, 2008
Bisphosphonates: mechanism of action and role in clinical practiceMatthew T Drake, Bart L Clarke, Suneep Khosla
Molecular Interventions|June 12, 2010
Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibitionMatthew T Drake, Serge C L M Cremers
Pageof 12